vs
Esperion Therapeutics, Inc.（ESPR）与医疗房产信托（SVC）财务数据对比。点击上方公司名可切换其他公司
医疗房产信托的季度营收约是Esperion Therapeutics, Inc.的1.8倍（$296.5M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs -17.0%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs -6.1%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
医疗房产信托（MPT）是总部位于阿拉巴马州伯明翰的国际房地产投资信托（REIT），主要在美国和欧洲地区收购投资医疗设施与营利性医疗控股公司。该公司的房产收购多采用售后回租模式，原产权方出售房产给MPT后成为承租租户，其租户普遍签订长期三净租约。
ESPR vs SVC — 直观对比
营收规模更大
SVC
是对方的1.8倍
$168.4M
营收增速更快
ESPR
高出160.7%
-17.0%
两年增速更快
ESPR
近两年复合增速
-6.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $296.5M |
| 净利润 | — | $-782.0K |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | -3.9% |
| 净利率 | — | -0.3% |
| 营收同比 | 143.7% | -17.0% |
| 净利润同比 | — | 99.0% |
| 每股收益（稀释后） | $0.32 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRSVC
| Q4 25 | $168.4M | $296.5M | ||
| Q3 25 | $87.3M | $377.6M | ||
| Q2 25 | $82.4M | $404.4M | ||
| Q1 25 | $65.0M | $335.0M | ||
| Q4 24 | $69.1M | $357.0M | ||
| Q3 24 | $51.6M | $390.9M | ||
| Q2 24 | $73.8M | $412.5M | ||
| Q1 24 | $137.7M | $336.2M |
净利润ESPRSVC
| Q4 25 | — | $-782.0K | ||
| Q3 25 | $-31.3M | $-46.9M | ||
| Q2 25 | $-12.7M | $-38.2M | ||
| Q1 25 | $-40.5M | $-116.4M | ||
| Q4 24 | — | $-76.4M | ||
| Q3 24 | $-29.5M | $-46.9M | ||
| Q2 24 | $-61.9M | $-73.8M | ||
| Q1 24 | $61.0M | $-78.4M |
营业利润率ESPRSVC
| Q4 25 | 50.6% | -3.9% | ||
| Q3 25 | -11.4% | -12.8% | ||
| Q2 25 | 8.6% | -9.2% | ||
| Q1 25 | -34.0% | -33.3% | ||
| Q4 24 | -6.4% | -19.4% | ||
| Q3 24 | -31.0% | -12.8% | ||
| Q2 24 | 3.5% | -17.1% | ||
| Q1 24 | 52.5% | -21.4% |
净利率ESPRSVC
| Q4 25 | — | -0.3% | ||
| Q3 25 | -35.9% | -12.4% | ||
| Q2 25 | -15.4% | -9.4% | ||
| Q1 25 | -62.2% | -34.8% | ||
| Q4 24 | — | -21.4% | ||
| Q3 24 | -57.2% | -12.0% | ||
| Q2 24 | -83.9% | -17.9% | ||
| Q1 24 | 44.3% | -23.3% |
每股收益（稀释后）ESPRSVC
| Q4 25 | $0.32 | $-0.01 | ||
| Q3 25 | $-0.16 | $-0.28 | ||
| Q2 25 | $-0.06 | $-0.23 | ||
| Q1 25 | $-0.21 | $-0.70 | ||
| Q4 24 | $-0.14 | $-0.46 | ||
| Q3 24 | $-0.15 | $-0.28 | ||
| Q2 24 | $-0.33 | $-0.45 | ||
| Q1 24 | $0.34 | $-0.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $346.8M |
| 总债务越低越好 | — | $5.5B |
| 股东权益账面价值 | $-302.0M | $646.1M |
| 总资产 | $465.9M | $6.5B |
| 负债/权益比越低杠杆越低 | — | 8.52× |
8季度趋势，按日历期对齐
现金及短期投资ESPRSVC
| Q4 25 | $167.9M | $346.8M | ||
| Q3 25 | $92.4M | $417.4M | ||
| Q2 25 | $86.1M | $63.2M | ||
| Q1 25 | $114.6M | $80.1M | ||
| Q4 24 | $144.8M | $143.5M | ||
| Q3 24 | $144.7M | $48.6M | ||
| Q2 24 | $189.3M | $14.6M | ||
| Q1 24 | $226.6M | $71.3M |
总债务ESPRSVC
| Q4 25 | — | $5.5B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $5.8B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ESPRSVC
| Q4 25 | $-302.0M | $646.1M | ||
| Q3 25 | $-451.4M | $647.9M | ||
| Q2 25 | $-433.5M | $695.9M | ||
| Q1 25 | $-426.2M | $734.6M | ||
| Q4 24 | $-388.7M | $851.9M | ||
| Q3 24 | $-370.2M | $929.0M | ||
| Q2 24 | $-344.2M | $1.0B | ||
| Q1 24 | $-294.3M | $1.1B |
总资产ESPRSVC
| Q4 25 | $465.9M | $6.5B | ||
| Q3 25 | $364.0M | $7.0B | ||
| Q2 25 | $347.1M | $6.9B | ||
| Q1 25 | $324.0M | $7.0B | ||
| Q4 24 | $343.8M | $7.1B | ||
| Q3 24 | $314.1M | $7.1B | ||
| Q2 24 | $352.3M | $7.1B | ||
| Q1 24 | $373.1M | $7.2B |
负债/权益比ESPRSVC
| Q4 25 | — | 8.52× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.85× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $-18.5M |
| 自由现金流经营现金流 - 资本支出 | — | $-95.2M |
| 自由现金流率自由现金流/营收 | — | -32.1% |
| 资本支出强度资本支出/营收 | 0.0% | 25.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-107.0M |
8季度趋势，按日历期对齐
经营现金流ESPRSVC
| Q4 25 | $45.2M | $-18.5M | ||
| Q3 25 | $-4.3M | $98.1M | ||
| Q2 25 | $-31.4M | $-7.0K | ||
| Q1 25 | $-22.6M | $38.2M | ||
| Q4 24 | $-35.0M | $-9.7M | ||
| Q3 24 | $-35.3M | $106.2M | ||
| Q2 24 | $-7.2M | $43.8M | ||
| Q1 24 | $53.8M | $-926.0K |
自由现金流ESPRSVC
| Q4 25 | — | $-95.2M | ||
| Q3 25 | — | $57.9M | ||
| Q2 25 | — | $-46.6M | ||
| Q1 25 | — | $-23.2M | ||
| Q4 24 | — | $-88.9M | ||
| Q3 24 | $-35.5M | $24.1M | ||
| Q2 24 | $-7.3M | $-22.3M | ||
| Q1 24 | $53.8M | $-77.2M |
自由现金流率ESPRSVC
| Q4 25 | — | -32.1% | ||
| Q3 25 | — | 15.3% | ||
| Q2 25 | — | -11.5% | ||
| Q1 25 | — | -6.9% | ||
| Q4 24 | — | -24.9% | ||
| Q3 24 | -68.7% | 6.2% | ||
| Q2 24 | -9.9% | -5.4% | ||
| Q1 24 | 39.0% | -23.0% |
资本支出强度ESPRSVC
| Q4 25 | 0.0% | 25.9% | ||
| Q3 25 | 0.0% | 10.6% | ||
| Q2 25 | 0.0% | 11.5% | ||
| Q1 25 | 0.0% | 18.3% | ||
| Q4 24 | 0.0% | 22.2% | ||
| Q3 24 | 0.3% | 21.0% | ||
| Q2 24 | 0.1% | 16.0% | ||
| Q1 24 | 0.1% | 22.7% |
现金转化率ESPRSVC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
SVC
暂无分部数据
